Kornimate/medical-research-clean huggingface dataset:
mcid in 30 sts test after pr in copd patients

Conditions: COPD

Summary: the sit-to-stand test (stst) is a feasible alternative for measuring peripheral muscle strength of the lower limbs. our aim was to evaluate, in chronic obstructive pulmonary disease (copd) patients, the minimal clinically important difference (mcid) of 30-second stst (30-stst) after pulmonary rehabilitation (pr). stable copd inpatients undergoing 30-stst and 6-minute walk test (6mwt) before and after pr were included. responsiveness to pr was determined by pre-to-post pr (δ) evaluation of 30-stst. the mcid was evaluated using an anchor-based method.

the sit-to-stand test (stst) is a feasible alternative for measuring peripheral muscle strength of the lower limbs used as standard test at the beginning and at the end of pulmonary rehabilitation programme. our aim was to retrospectively evaluate, in chronic obstructive pulmonary disease (copd) patients, the minimal clinically important difference (mcid) of 30-second stst (30-stst) after pulmonary rehabilitation (pr). stable copd inpatients undergoing 30-stst and 6-minute walk test (6mwt) before and after pr were included. responsiveness to pr was determined by pre-to-post pr (δ) evaluation of 30-stst. the mcid was evaluated using an anchor-based method.

Eligibility criteria:
inclusion criteria: * diagnosis for copd according to the gold criteria. * no exacerbations over the previous four weeks - page 3 of 3 - * completing pr program * smoking history ≥10 pack years * regular treatment with inhaled bronchodilators and inhaled steroids exclusion criteria: * any unstable medical condition * contraindications for participation in the pr program included musculoskeletal disorders, malignant diseases, unstable cardiac condition, and lack of adherence to the program -

Keywords: mcid 30 sts test pulmonary rehabilitation
safety study of avp-923 in the treatment of ieed (involuntary emotional expression disorder) also known as pseudobulbar affect (episodes of uncontrolled crying and/or laughter)

Conditions: Alzheimer's Disease; Stroke; Parkinson's Disease; Traumatic Brain Injury

Summary: the purpose of this study is to evaluate the long-term safety of avp-923 in the treatment of involuntary emotional expression disorder (ieed) also known as pseudobulbar affect (episodes of uncontrolled crying and/or laughter).

this is an "open label" study which means there is no placebo group. each subject enrolled into the study will receive avp-923.

Eligibility criteria:
inclusion criteria: * 18 to 75 years of age, inclusive * clinical diagnosis of pba (pseudobulbar affect) * if female, must not be pregnant or breast feeding exclusion criteria: * sensitivity to quinidine or any opiate drugs * current or prior history of major psychiatric disturbance * currently participated in a trial within the past 30 days

Keywords: als ms cns ad tbi dextromethorphan ieed emotional
peri-implantitis, comparing treatments 970 nm laser and mucosal flap surgery

Conditions: Peri-Implantitis

Summary: a clinical trial comparing laser treatment and conventional mucosal flap surgery for treatment of peri-implantitis. the main aim of the study is to evaluate if treatment of peri-implantitis with 970 nm laser combined with scaling and root planning (srp) is clinically comparable to conventional mucosal flap surgery in terms of pocket probing depth reduction.

the present project aims to evaluate a novel method in treating peri-implantitis, with focus on decreasing the patient's suffering as well as disease progression. peri-implantitis has a direct influence on both physical and psychological wellbeing and have been related to difficulty in chewing due to loss of implants, bad esthetic appearance as well as high costs. therefore, it is of importance for the individual as well as for the society to thoroughly investigate any new treatment approaches. the study is a prospective randomized clinical trial comparing laser treatment (test group) and conventional mucosal flap surgery (active control group). assessment of clinical variables at baseline and after 6 months. patient reported outcomes at baseline, directly after treatment and after 10 days. primary objective: to evaluate if treatment of peri-implantitis with 970 nm laser combined with scaling and root planning (srp) is clinically comparable to conventional mucosal flap surgery in terms of pocket probing depth reduction. secondary objectives: * to evaluate other clinical and radiological variables connected to peri-implantitis and the inflammation surrounding the dental implant. * to evaluate the patient experience of treatment of peri-implantitis. * to evaluate the inflammatory and microbial response after laser treatment

Eligibility criteria:
inclusion criteria: * signs of peri-implantitis around one or more dental implants. all criteria below need to be fulfilled for inclusion. * presence of pocket probing depth (ppd) \> 5 mm * bleeding on probing/suppuration (bop/pus) * at least 2 mm loss of bone, visible on radiographs, after initial osseointegration. * ≥ 18 years old. * patient able to understand swedish. exclusion criteria: * antibiotic treatment 6 months prior to baseline. * peri-implant treatment 6 months prior to baseline. * myocardial infarction 6 months prior to baseline. * previous radiation treatment in the affected jaw area. * previous i.v. bisphosphonate treatment. * moderate or severe impairment of cognitive function (e.g. dementia).

Keywords: peri-implantitis laser treatment surgical treatment randomized controlled trial patient reported outcomes clinical outcomes microbiology immunology
to investigate the bone and muscle abnormalities in patients with chronic kidney disease with mri

Conditions: Chronic Kidney Disease-Mineral and Bone Disorder

Summary: patients with chronic kidney disease (ckd) have a higher risk of fractures than those without. the purpose of this study is to develop a non-invasive magnetic resonance imaging (mri) method that can improve fracture risk prediction and provide early diagnosis for bone abnormalities in patients with ckd.

chronic kidney disease-mineral and bone disorder (mbd） is a common complication of chronic kidney disease (ckd), which may lead to defective mineralization, altered bone morphology, and/or bone turnover. animal research found that bone changes occur even in the early stage of ckd , and with ckd progression, the patient may show symptoms such as bone pain, joint pain, bone deformation, and even spontaneous fractures. despite significant advances in understanding bone disease in ckd, most clinical and biochemical targets used in clinical practice remain controversial, resulting in an undermanagement of bone fragility.our ability to diagnose ckd-mbd and to initiate strategies that could prevent fractures remains limited by the lack of accurate and noninvasive diagnostic tools. the purpose of this study is to develop a non-invasive method that can improve fracture risk prediction and provide early diagnosis for bone abnormalities in patients with ckd.

Eligibility criteria:
inclusion criteria: ckd patients aged 18-70 years with free movement - exclusion criteria: 1. the following diseases: rickets, osteomalacia, paget's disease, acromegaly, scurvy (vitamin c deficiency), hyperthyroidism, history of malignant tumors, received radiotherapy and chemotherapy, fractures within 6 months, lumbar and calf trauma surgery, scoliosis, rheumatic immunity disease, anorexia nervosa, motor neuron disease 2. treated with the following drugs within two years: a) bisphosphonates: alendronate , etidronate , ibandronate, rithiadronate, and zoledronate b) steroid hormones: estrogen replacement agents , isoflavone derivatives , estrogen, progesterone c) oral glucocorticoids: prednisone , prednisone d) salmon calcitonin 3. mri contraindications: intra uterine device(iud), pacemaker, cochlear implant, claustrophobia, etc -
platelets in cystic fibrosis lung inflammation

Conditions: Platelet Levels and Mean Platelet Volume in Patients With CF

Summary: cystic fibrosis (cf) is a chronic multiorgan disorder caused by mutations in the cftr (cystic fibrosis transmembrane conductance regulator) gene. chronic airway infection by bacterial pathogens accounts for the progressive, suppurative pulmonary disease that leads to significant morbidity and mortality in patients with cf. neutrophil recruitment to the lungs accounts the most important contributor to pulmonary destruction. however, there is evidence that platelets may also have an important role in the pathogenesis of inflammation. to our knowledge, there is few information in platelet levels in patients with cystic fibrosis during pulmonary exacerbation, chronic airway colonization and when stable.

airway inflammation in cf is predominantly neutrophilic in nature with increased concentrations of pro-inflammatory mediators include tnf-α, il-1β, il-6, il-8, il-17, il-33, gm-csf and g-csf. in addition, other cell types including macrophages and t-lymphocytes are expressed by cftr and contribute to the cf inflammatory response. researches have indicated that platelets may also have a significant contribution to the inflammation. platelet depletion or antiplatelet therapies attenuate injury and mortality in animal models of acute lung injury. more importantly, cftr expression has been shown on human platelets. recent data suggests that cf patients have an increase in circulating activated platelets and platelet reactivity. taken together, these observations support a potentially important role of platelets in regulating lung inflammation in cf. however, there are few studies examine platelet and lung inflammation interraction in patients with cf. therefore we aimed to investigate platelet count (pc) and mean platelet volume (mpv) levels in various conditions in our cf patients.

Eligibility criteria:
inclusion criteria: * all regularly followed cystic fibrosis patients with clinical and laboratory results could be obtained from medical charts. exclusion criteria: * none

Keywords: cystic fibrosis, platelet count, mean platelet volume
studying biomarkers in samples from younger patients with malignant germ cell tumor progression

Conditions: Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor

Summary: rationale: studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors find better ways to treat cancer. purpose: this research trial studies samples from younger patients with malignant germ cell tumor progression.

objectives: * explore inter-tumoral heterogeneity in dna methylation by tumor histology. * determine the genomic methylation pattern in the tumors. * correlate methylation pattern with tumor histology and clinical characteristics. * carry out exome capture and massively parallel sequencing on selected germ cell tumors (gcts) and matched normal tissue. * perform exome capture and solexa sequencing on a selected set of gcts. * validate candidate mutations in an independent set of tumors. * determine the expression profile of mrnas, lincrnas and micrornas in the tumors using rna seq. outline: archived blood and tumor tissue samples are analyzed for genomic methylation pattern, exome capture and sequencing, and candidate mutations by methylation-specific pcr techniques, single nucleotide polymorphism (snp) arrays, and solexa sequencing methods. results are validated by using pyrosequencing assays and primer-extension assays. methylation pattern is also associated with each patient's tumor histology and clinical data.

Eligibility criteria:
disease characteristics: * tumor and blood specimens from patients registered on the children oncology group (cog) germ cell tumor protocols, and from other study sites for non-cog patients, including children's medical center, dallas and the dana-farber cancer institute, boston * patients' clinical data patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent childhood malignant germ cell tumor recurrent extragonadal germ cell tumor recurrent malignant testicular germ cell tumor recurrent ovarian germ cell tumor
prophylactic application of an incisional wound vac to prevent wound complications in obese spine surgery patients

Conditions: Spine Surgery; Wounds Vac

Summary: this is a prospective randomized study evaluating the use of a prophylactic incision wound vac dressing, applied in the or, on patients undergoing posterior spine surgery with a bmi\>35. patients are randomized in the operating room to normal postoperative dressing vs. vac dressing. the vac dressing would be left on for 72 hours postoperatively. in the interim, the patients' postoperative care can proceed as usual. our primary outcomes will be antibiotics or return trip needed to the operating room for wound related complications. the patients only intervention would be the application of an incisional wound vac. the will be no change in the patients postoperative protocol otherwise. this procedure is noninvasive.


Eligibility criteria:
inclusion criteria: * be scheduled to have posterior spine surgery (inpatient procedures only). * have a bmi greater than or equal to 35. exclusion criteria: * bmi less than 35 * previous spine infection * intraoperative dural tear
prednisolone-induced beta-cell dysfunction prevented by exenatide

Conditions: Glucocorticoid-induced Glucometabolic Abnormalities; Glucocorticoid-induced Beta-cell Dysfunction

Summary: the purpose of this study is to explore whether the glp-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.


Eligibility criteria:
inclusion criteria: * written informed consent * 18 years ≤ age ≤ 35 years on the day of the first visit * 22.0 ≤ bmi ≤ 28.0 kg/m2 * (history of) good physical and mental health as determined by history taking, physical and laboratory examinations and ecg. * fasting glucose level of \< 5.6 mmol/l, in addition to a glucose level of \< 7.8 mmol/l at 2 hours after intake of 75 g glucose (ogtt). * able to keep a normal day and night rhythm during the trial period (i.e. no shift work) exclusion criteria: * history or presence of a medical disorder * use of drugs, except for incidental (non-opioid) analgesic agents * first degree relative with t2dm * performing intensive physical activity \> 1x/week * an allergic or anaphylactic reaction to prednisolone treatment in the past * clinically relevant history or presence of any medical disorder, which are mentioned in the summary of product characteristics (spc) as contraindication for the use of prednisolone * glucocorticosteroid use during the last three months prior to the first dose * participation in an investigational drug trial within 90 days prior to the first dose * donation of blood (\> 100 ml) within 90 days prior to the first dose * history of or current abuse of drugs or alcohol (\>14 u/week) * smoking * use of grapefruit products during the study period * recent changes in weight and/or physical activity * serious mental impairment or language problems i.e. preventing to understand the study protocol/aim
safety and efficacy study of doxycycline in combination with interferon-b-1a to treat multiple sclerosis

Conditions: Multiple Sclerosis

Summary: to evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple sclerosis (rrms) having breakthrough disease activity.

eligible individuals were evaluated monthly for 3 months while taking intramuscular interferon beta-1a, 30 micrograms weekly, then monthly for 4 months while receiving intramuscular interferon beta-1a, 30 micrograms and oral doxycycline, 100 mg daily.

Eligibility criteria:
inclusion criteria: * age 18-55 * relapsing-remitting multiple sclerosis (rrms) * avonex therapy for 6 months prior continuous * annualized relapse rate \>2 during avonex therapy * most recent relapse within 60 days of baseline * entry expanded disability status scale (edss) 1.5-4.5 * one or more gadolinium (gd+) mri lesions on a baseline mri * no history of immune modulator or immunosuppressant therapy used in combination with avonex (other then gsc administer for clinical relapses) * not participating in any other study of ms therapeutics * serum neutralizing antibodies (nabs) titer to avonex \<20 exclusion criteria: * medical or psychiatric conditions that will affect patients ability to provide informed consent * inability to undergo mri * clinically serious medical conditions or significantly abnormal labs * no use of these medications or procedures within six months prior to study: \*monoclonal antibodies,total lymphoid radiation,systemic steroids,cytotoxic or immunosuppressive medications such as mitoxantrone or cyclophosphamide or any other investigational drugs * interferon neutralizing antibody titers \>20 * no breast feeding or pregnant * no patients with any systemic illness,psychiatric condition or other disorder that would concern safety of patient to complete procedures of protocol * abnormal blood test * clinically significant abnormality on chest x-ray (cxr)
couples coping with alzheimer's disease

Conditions: Aging; Alzheimer Disease; Dementia

Summary: the purpose of this study is to test the efficacy of a new couples counseling intervention for people recently diagnosed with early alzheimer's disease and their spouses. the study hypothesis is that counseling the couple shortly after the diagnosis, and while the functional impact of the illness is still relatively mild, will have a significant impact on their ability to provide support for each other.

the majority of people with alzheimer's disease (ad) live at home with their spouses. ad erodes the ability of each member of the couple to support each other. moreover, couples may be unaccustomed to seeking or accepting emotional and practical support from family members or formal resources. even though ad can have a major negative impact on each member of the couple and on their relationship, their needs have generally been addressed separately, often without sufficient appreciation for the importance of their ongoing relationship. previous studies suggest that by improving support for both members of the couple, the intervention will have a positive effect on mental health outcomes such as depression and help keep the person with ad at home rather than in a long-term care facility. one hundred couples will be randomly assigned either to an immediate treatment group or a wait-list control group which will receive treatment four months after enrollment. participants will receive a formal baseline assessment, consisting of a structured set of questionnaires to assess dyadic (couple) adjustment, social support, depression and anxiety as well as goals for counseling. there will be two follow-up assessments, 2 and 4 months after baseline using the same instruments. all participants will be able to call a counselor for the duration of the study to obtain resource and referral information or in the event of a crisis. the treatment will consist of 6 sessions of couples counseling within a 2-month period. the focus will be on helping each member of the couple to express feelings, needs and issues that have emerged between them as a result of the diagnosis.

Eligibility criteria:
inclusion criteria: * couples, in which one partner has been diagnosed with ad and is in the mild stage of the disease * ages 21 to 90 exclusion criteria: * severe psychological or physical illness * unwillingness to participate in all aspects of the study

Keywords: caregivers caregiving spousal relationships cognition disorders therapy mental health psychosocial
use of antibiotic carrier in acute periprosthetic infections (appi) of total knee replacements

Conditions: Infection

Summary: the purpose of the study is to gather information on the use of stimulan, the surgery, and anitbiotics to whetether the appi has decreased or shown improvement when compared to study participants who did not receive stimulan during their revision total knee replacement surgery.


Eligibility criteria:
inclusion criteria: * appi within 28 days of primary tkr * acute hematogenous infection within 4 weeks of symptoms exclusion criteria: * exposed prosthesis * infection occuring in revised joints * poly articular infections * have allergies to tobramycin or vancomycin * previous chronic infections in or around any ipsilateral extremity trauma or implants

Keywords: total knee replacment infection stimulan
a study of obinutuzumab evaluating efficacy, safety and cost of disease management in participants with chronic lymphocytic leukemia and comorbidities

Conditions: Chronic Lymphocytic Leukemia

Summary: this multicenter, single arm, non-interventional, observational study will evaluate the efficacy and safety of obinutuzumab in daily clinical practice in participants with chronic lymphocytic leukemia (cll). the study will also assess cost of disease management. the total length of the study is 42 months.


Eligibility criteria:
inclusion criteria: * participants with untreated cll and comorbidities, for which the physician has already decided to use obinutuzumab in association with chlorambucil exclusion criteria: * participation in another clinical trial during the study
the development of skin adhesive patches for the monitoring and prediction of mental disorders

Conditions: Major Depressive Disorder, Anxiety Disorder

Summary: development of skin adhesive patches for the monitoring and prediction of mental disorders


Eligibility criteria:
inclusion criteria: * the existence of a current major depressive disorder or panic disorder during the screening and baseline visits, per the mini-international neuropsychiatric interview (sheehan et al., 1998) according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * scored at least 16 on the hdrs-17 (hamilton, 1960) for mdd and 7 on the panic disorder severity scale for panic disorder patients at the baseline visits. exclusion criteria: * patients who had psychotic disorder (e.g., schizophrenia or delusional disorder), bipolar affective disorder,active alcohol or drug use disorder, neurological illness including significant cognitive impairment or parkinson's disease, mental retardation, significant medical conditions, epilepsy, histories of alcohol or drug dependence, personality disorders, or brain damages * patients who were at serious risk for suicide of homicide
geriatric head trauma short term outcomes project

Conditions: Head Injury; Anticoagulant-induced Bleeding; Fall

Summary: this prospective observational study will examine the incidence of intracranial hemorrhage. the investigators will compare patients on anticoagulant and/or antiplatelet therapy with head trauma compared to patients not on these medications. while many studies have sought to quantify the incidence of intracranial hemorrhage in these patients, there is considerable controversy regarding their care and what to do after an initial negative head ct in anticoagulated geriatric patients who have experienced head trauma.


Eligibility criteria:
inclusion criteria: patients seen in the emergency department for head trauma exclusion criteria: penetrating head trauma